dronabinol has been researched along with Chronic Progressive Multiple Sclerosis in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cantello, R; Naldi, P; Spagarino, A; Varrasi, C; Vecchio, D; Virgilio, E | 1 |
| Bianco, A; De Fino, C; Losavio, F; Lucchini, M; Mirabella, M; Nociti, V; Sabino, A; Santoro, M | 1 |
| Ball, S; Cano, MG; Hobart, J; Mallik, S; McManus, D; Miller, D; Nunn, A; Vickery, J; Wright, D; Zajicek, J | 1 |
| Paul, F; Stuve, O | 1 |
| Baker, D; Giovannoni, G; Pryce, G; Riddall, DR; Selwood, DL | 1 |
| Ball, S; Cano, MG; Green, C; Hobart, J; MacManus, D; Mallik, S; Miller, D; Nunn, A; Shearer, J; Vickery, J; Wright, D; Zajicek, J | 1 |
| Baker, D; Pryce, G | 1 |
| Amadio, S; Comi, G; Del Carro, U; Houdayer, E; Leocani, L; Martinelli, V; Nuara, A; Rossi, P; Schiavetti, I; Sormani, MP; Straffi, L; Vila, C | 1 |
| Gajofatto, A | 1 |
| Baakman, AC; Beumer, TL; Cohen, A; Groeneveld, GJ; Heuberger, J; Kanhai, K; Killestein, J; Klaassen, E; Strijers, RLM; van Amerongen, G; van Gerven, J | 1 |
| Aragona, M; Bettolo, CM; Conte, A; Frasca, V; Gabriele, M; Giacomelli, E; Gilio, F; Iacovelli, E; Inghilleri, M; Onesti, E; Pantano, P; Pozzilli, C; Tomassini, V | 1 |
| Davies, P; Langford, R; Notcutt, W; Potts, R; Ratcliffe, S | 1 |
2 review(s) available for dronabinol and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Topics: Adult; Cannabinoid Receptor Agonists; Disease Progression; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Treatment Outcome | 2013 |
Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.
Topics: Animals; Cannabinoids; Cannabis; Dose-Response Relationship, Drug; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Humans; Medical Marijuana; Mice; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents | 2015 |
8 trial(s) available for dronabinol and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Cannabinoids in multiple sclerosis: A neurophysiological analysis.
Topics: Administration, Oral; Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Muscle Spasticity; Muscle, Skeletal; Pain; Pilot Projects; Treatment Outcome | 2020 |
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Interferon beta-1b; Leukocytes, Mononuclear; Male; Methylation; Middle Aged; Multiple Sclerosis, Chronic Progressive; Promoter Regions, Genetic; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2017 |
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Topics: Adult; Cannabinoid Receptor Agonists; Disease Progression; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Treatment Outcome | 2013 |
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Topics: Administration, Oral; Adult; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Dronabinol; Female; Financing, Government; Financing, Personal; Humans; Kaplan-Meier Estimate; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Muscle Spasticity; Neuroimaging; Outcome Assessment, Health Care; Proportional Hazards Models; Quality-Adjusted Life Years; Severity of Illness Index; Time Factors; United Kingdom | 2015 |
Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
Topics: Adult; Cannabidiol; Cerebral Cortex; Cross-Over Studies; Double-Blind Method; Dronabinol; Drug Combinations; Electric Stimulation; Electromyography; Evoked Potentials, Motor; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Muscle Spasticity; Outcome Assessment, Health Care; Plant Extracts; Severity of Illness Index; Transcranial Magnetic Stimulation | 2015 |
Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis.
Topics: Administration, Oral; Adult; Aged; Cognition; Cross-Over Studies; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Muscle Spasticity; Neuralgia; Pain Measurement; Proof of Concept Study | 2018 |
Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
Topics: Administration, Oral; Adult; Afferent Pathways; Analgesics; Cannabinoids; Central Nervous System; Cross-Over Studies; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neural Conduction; Nociceptors; Pain; Pain Measurement; Pain Threshold; Placebos; Reaction Time; Reflex; Treatment Outcome | 2009 |
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
Topics: Aged; Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Muscle Spasticity; Placebos; Plant Extracts; Substance Withdrawal Syndrome | 2012 |
3 other study(ies) available for dronabinol and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Progressive multiple sclerosis: desperately seeking remedy.
Topics: Cannabinoid Receptor Agonists; Dronabinol; Female; Humans; Male; Multiple Sclerosis, Chronic Progressive | 2013 |
Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis.
Topics: Cost-Benefit Analysis; Dronabinol; Female; Humans; Male; Multiple Sclerosis, Chronic Progressive; Quality-Adjusted Life Years | 2015 |
Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis.
Topics: Cannabidiol; Cannabinoid Receptor Modulators; Dronabinol; Drug Combinations; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Muscle Relaxants, Central; Muscle Spasticity; Trigeminal Neuralgia | 2016 |